Oss, March 30th, 2017 – NTRC announces its GeneNominator™ bioinformatics package to study the biology of inhibitor response at the mRNA expression level. With NTRC’s Oncolines™ panel, the IC50 values of inhibitors can be determined in a rapid and reproducible fashion. With the new GeneNominator™ tool, these IC50 values can be connected to the expression levels of more than 18,000 individual genes in each of the cell lines. This enables identification of pathways that confer sensitivity or resistance to customer inhibitors. False positive scoring genes are filtered out by comparing responses with a proprietary database of response profiles of 150 different drugs and drug candidates. Interesting genes are highlighted through the use of relevant subsets. GeneNominator™ makes use of state-of-the-art analyses such as protein-protein-interaction predictions and Gene Set Analysis to give meaning to gene lists and identify the important pathways in responsive and resistant cell populations. This includes the prediction of responder populations at the clinical level.
GeneNominator™ will be presented at the NTRC booth (#3050) at the American Association of Cancer Research 2017 Annual meeting in Washington D.C. For more information: firstname.lastname@example.org.
MDM2 gene expression in cell lines, which inhibits TP53 activity, strongly correlates with sensitivity for the MDM2 inhibitor nutlin-3a (left). This is complementary to the Oncolines™ genomic biomarker association which shows that TP53 wild type cell lines are sensitive for nutlin-3a (right).
NTRC is a precision medicine company dedicated to the development of new anti-cancer drugs. NTRC facilitates the development of novel therapies by providing cancer cell line profiling services (Oncolines™, OncolinesProfiler™, and SynergyFinder™) and target residence time measurements for protein kinases (ResidenceTimer™) on a fee-for-service basis. NFK GreenScreen™, an assay read-out for the cancer immunotherapy drug targets IDO1 and TDO, is supplied to clients globally. For more information please visit www.ntrc.nl or contact email@example.com